Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.
from The Medical News http://ift.tt/1aJUM4v
Our mission is to advice, and to make the people of the world healthier through the power of information.
No comments:
Post a Comment